PTO/SB/08A (10-01)

use through 10/31/2002.OMB 0651-0031 be: U.S. DEPARTMENT OF COMMERCE U. S. Patent and Tradema

Substitute for form 1449A/PTO				Complete if Known		
Substitute 15th 15th 144524 75				Application Number	10/009,709	
INFORMATION DISCLOSURE				Filing Date	November 16, 2001	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Nicklas Stromberg	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \				Art Unit	N/A	
E/	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Siteet	1	of	1	Attorney Docket Number	C2432.0044/P044	

U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where Relevant Document Number Publication Date Name of Patentee or Applicant MM-DD-YYYY of Cited Document Passages or Relevant No. Number-Kind Code<sup>2</sup> (#known) Figures Appear 4,225,579 09-30-1980 | Kleinberg

FOREIGN PATENT DOCUMENTS						
Evernines	Cito	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Γ
Evaminer Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				τ⁵
(Xi	В	WO-99/14231-A2	03-25-1999	Forssmann		X
	С	WO-94/07523-A1	04-14-1994	Emory University		X
(War	D	WO-00/69890-A1	11-23-2000	Stromberg		X

Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	E	YASUO YAMAUCHI, ET AL, "Recombinant and Native Zymogen Forms of Human Complement /Factor D <sup>1</sup> , Journal of Immunology, 1994, pp. 3645-3652, vol. 152.		

Examiner Date Signature Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

g mi Hicklas Stromberg

Application No.: 10/009,709

Group Art Unit: N/A

Filed: November 16, 2001

Examiner: Not Yet Assigned

For: PREVENTION OF DENTAL CARIES

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

## Timing of Filing of the Information Disclosure Statement:

[×]	This IDS is being filed before the First Office Action'.
	This IDS is being filed after the issuance of the First Office Action but before the
	issuance of a Final Office Action <sup>2</sup> .

<sup>&</sup>lt;sup>1</sup> The IDS should, where possible, include a certification under 37 C.F.R. §1.97(e).

<sup>&</sup>lt;sup>2</sup> The IDS must include either a certification under 37 C.F.R. §1.97(e) or the fee set forth in 37 C.F.R. §1.17(p).

Appli	ication No.: 10/009	Dock To.: C2432.0044/P044
	This IDS is being filed after the issuance of a Fina payment of the Final Fee <sup>3</sup> .	l Office Action but before the
Certi	ifications:	
If che	ecked, the undersigned makes the following stateme	ent(s):
	Statement under 37 CFR § 1.97(e):	
	Each item of information contained in this information cited in any communication from a foreign patent application not more than three months prior to the statement; or	office in a counterpart foreign
	No item of information contained in this information a communication from a foreign patent office in a to the knowledge of the undersigned after making information contained in this information disclosure individual designated in § 1.56(c) more than three information disclosure statement.	counterpart foreign application, and greasonable inquiry, no item of are statement was known to any
	Statement Under 37 C.F.R. § 1.704(d):	
	Each item of information contained in this inform in a communication from a foreign patent office in communication was not received by any individua	a counterpart application and this

thirty days prior to the filing of this information disclosure statement.

<sup>&</sup>lt;sup>3</sup> The IDS must include both a certification under 37 C.F.R. §1.97(e) and the fee set forth in 37 C.F.R. §1.17(p).

Fee Required by 37 C.F.R. 1.97(c)(2) or 1.97(d)(2): If checked, the fee of \$180.00 set forth in 37 C.F.R. \$1.17(p) is attached. Copies of Information: In accordance with 37 C.F.R. §1.98(a), the following are enclosed:  $\boxtimes$ A legible copy<sup>4</sup> of each document (or relevant portion thereof) is cited in the attached PTO/SB/08. With respect to any information which is not in English, a concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information, is attached. This concise explanation is provided by way of: A translation of the relevant portions of the non-English language information<sup>5</sup>; A statement explaining the relevant portions of the non-English language information; A copy [and, where not in the English language, a translation] of at least the relevant portion(s)<sup>6</sup> of the communication from a foreign patent office in a counterpart foreign application in which the information was cited; or

<sup>&</sup>lt;sup>4</sup> A legible copy of the document is not required if (1) the information was previously cited by, or submitted to, the Office and considered by the Office in a prior U.S. application to which this application claims priority, provided that the prior application is properly identified in this IDS, and (2) the IDS submitted in the earlier application complies with 37 C.F.R. § 1.98(a) - (c). This exception does not apply to information cited in an International Application.

<sup>&</sup>lt;sup>5</sup> 37 C.F.R. §1.98(a)(3)(ii) requires that an English language translation be provided when a translation of the document, or portion thereof, "is within the possession, custody or control of, or is readily available to any individual designated in 37 C.F.R. § 1.56(c)."

Application No.: 10/009

Dock No.: C2432.0044/P044

This information is contained in the specification of the present application.

## Materiality:

Whether or not the information and references disclosed in this Information Disclosure Statement is "material" pursuant to 37 CFR 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Dated: April 18, 2002

Respectfully submitted,

Edward A. Meilman

Registration No.: 27,735

DICKSTEIN SHAPIRO MORIN &

OSHINSKY LLP

1177 Avenue of the Americas, 41st Floor

ward G. Malin us

New York, NY 10036-2714

(212) 835-1400

Attorneys for Applicant

<sup>&</sup>lt;sup>6</sup> The relevant portion is that portion which indicates the degree of relevance found by the foreign patent office. This may be an explanation of which portion of the of the reference is particularly relevant, to which claims it applies, or merely an "X", "Y", or "A" indication on a search report. MPEP §609 III A(3).